SEARCH:   Advanced

Blood, 29 October 2009, Vol. 114, No. 18, pp. 3757-3763. Prepublished online as a Blood First Edition Paper on August 7, 2009; DOI 10.1182/blood-2009-04-218651. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2009-04-218651v1 114/18/3757    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Google Scholar Articles by Hölig, K. Articles by Ehninger, G. PubMed PubMed Citation Articles by Hölig, K. Articles by Ehninger, G. Related Collections Hematopoiesis and Stem Cells Transfusion Medicine Transplantation Free Research Articles Clinical Trials and Observations Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donors Kristina Hölig1, Michael Kramer1, Frank Kroschinsky1, Martin Bornhäuser1, Thilo Mengling2, Alexander H. Schmidt2, Claudia Rutt2, and Gerhard Ehninger1 1 Department of Internal Medicine I, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden; and 2 DKMS German Bone Marrow Donor Center, Tübingen, Germany We present results of peripheral blood stem cell (PBSC) mobilization, collection, and follow-up from 3928 consecutive unrelated stem cell donors. Assessments were performed prospectively at baseline, leukapheresis, 1 month, 6 months, and annually after PBSC donation. During follow-up, side effects were recorded by return post questionnaires. The median CD34+ cell counts on day 5 were 67.5/µL in male and 51/µL in female donors. Bone pain and headache were the most common side effects of recombinant human granulocyte-colony stimulating factor. Central venous access was required for 23 donations (0.6%). Throughout the follow-up, the absolute neutrophil counts were slightly below the initial baseline values but remained within the normal range. The majority of the donors reported good or very good health. Malignancies occurred in 12 donors (0.3%), among whom were 1 case of acute myeloid leukemia, 1 case of chronic lymphatic leukemia, and 2 cases of Hodgkin disease. Only the incidence of Hodgkin lymphoma differed significantly from an age-adjusted population. In conclusion, 7.5 µg/kg per day lenograstim proved to be safe and effective for mobilizing hematopoietic stem cells for allogeneic transplantation. Long-term monitoring of healthy PBSC donors remains important to guarantee the safety standards of PBSC mobilization and collection. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Donors, donors, and more donors Paolo Anderlini Blood 2009 114: 3721-3722. [Full Text] [PDF] This article has been cited by other articles: P. Anderlini Donors, donors, and more donors Blood, October 29, 2009; 114(18): 3721 - 3722. [Full Text] [PDF]

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020